Berlow B A, Liebhaber M I, Dyer Z, Spiegel T M
Allergy and Immunology Division, Sansum Medical Clinic, Santa Barbara, CA 93105.
J Allergy Clin Immunol. 1991 Mar;87(3):710-5. doi: 10.1016/0091-6749(91)90393-3.
We studied the steroid-sparing effect of dapsone in 10 subjects with chronic asthma in a preliminary open trial. Dapsone was chosen because it inhibits neutrophil function and possesses anti-inflammatory effects in a variety of disorders. The study group consisted of 10 subjects with stable, steroid-dependent asthma, aged 23 to 80 years, with normal glucose-6-phosphate dehydrogenase levels. Average daily baseline prednisone dose ranged from 5 to 60 mg. Dapsone, 100 mg, twice daily, by mouth, was started after a 1-month baseline period. Baseline steroid dose, symptom scores, and daily peak flow rates were compared to the latest available 4-week period of dapsone treatment. Average cumulative monthly prednisone dose was reduced from 428 mg to 82 mg (p less than 0.02). Five of 10 patients stopped steroids by month 6 and two additional patients by month 13. Two additional patients demonstrated a coincidental 74% reduction in steroid dose, and one patient demonstrated no response. Clinical parameters remained stable despite steroid reduction. These preliminary data suggest dapsone may have steroid-sparing effects in chronic asthma.
我们在一项初步的开放性试验中，对10名慢性哮喘患者研究了氨苯砜的激素节省效应。选择氨苯砜是因为它能抑制中性粒细胞功能，并且在多种疾病中具有抗炎作用。研究组由10名年龄在23至80岁、葡萄糖-6-磷酸脱氢酶水平正常的稳定的激素依赖型哮喘患者组成。泼尼松的平均每日基线剂量为5至60毫克。在1个月的基线期后，开始口服氨苯砜，每日2次，每次100毫克。将基线期的激素剂量、症状评分和每日峰值流速与氨苯砜治疗的最新可用4周期间进行比较。平均每月累积泼尼松剂量从428毫克降至82毫克（p<0.02）。10名患者中有5名在第6个月停用了激素，另外2名患者在第13个月停用。另有2名患者的激素剂量意外减少了74%，1名患者无反应。尽管激素减少，但临床参数仍保持稳定。这些初步数据表明，氨苯砜在慢性哮喘中可能具有激素节省效应。
